The present study sought to determine, in more detail, the effects of an unselective and a
selective adenosine A2A receptor blockade on catalepsy induced by a blockade of …

The future management of Parkinson's disease (PD) requires pharmacologic agents that do
not lose efficacy with disease progression or induce dyskinesia and that are free of other …

Repetitive behaviors are diagnostic for autism and common in related neurodevelopmental
disorders. Despite their clinical importance, underlying mechanisms associated with the …

Rationale Istradefylline, an adenosine A 2A receptor antagonist, improves motor function in
animal models of Parkinson's disease (PD) and in patients with PD. In addition, some A 2A …

The development of non-dopaminergic therapies for the treatment of Parkinson's disease
(PD) has attracted much interest in recent years. Among new different classes of drugs …

The aim of the present study was to find out whether blockade of adenosine A2A receptors
by a selective antagonist, SCH 58261, influenced parkinsonian‐like muscle rigidity. Muscle …

Adenosine and dopamine interact antagonistically in living mammals. These interactions are
mediated via adenosine A2A and dopamine D2 receptors (R). Stimulation of A2AR inhibits …

Research and development of the adenosine A2A receptor selective antagonist KW6002
have focused on developing a novel nondopaminergic therapy for Parkinson's disease (PD) …

Parkinson's disease (PD) is one of the most prevalent neurodegenerative disease
displaying negative impacts on both the health and social ability of patients and …

Obesity predisposes humans to a range of life-threatening comorbidities, including type 2
diabetes and cardiovascular disease. Obesity also aggravates neural pathologies, such as …